Controlled-Release C-O-P Derivatives for Kidney Failure Calcification
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current therapies fail to effectively inhibit or treat kidney failure-related diseases, particularly cardiovascular calcification and bone mineral disorders, in patients with renal impairment due to rapid compound elimination and lack of sustained therapeutic levels.
Innovation Solution
Administering compounds with C—O—P bonds in a prolonged release form to maintain adequate blood levels for an extended period, preventing irreversible binding to calcium-containing crystals and reducing side effects.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If compounds with C-O-P bonds are administered to patients with kidney failure, then therapeutic effect is improved, but rapid elimination reduces duration of action
Solution Approach 1:
The compound administration is segmented into multiple small doses distributed over time rather than a single large dose. This maintains sustained therapeutic levels in the blood by preventing rapid elimination, allowing the compound to exert its therapeutic effect on calcium-containing crystal binding while avoiding the rapid clearance issue that limits duration of action in kidney failure patients
Solution Approach 2:
The treatment employs continuous or near-continuous administration of the compound through prolonged infusion or multiple dosing regimens. This ensures uninterrupted therapeutic action by maintaining constant blood levels of the compound, overcoming the rapid elimination characteristic of kidney failure patients and ensuring continuous binding to calcium-containing crystals
2Speed
If bolus or short infusion administration is used, then rapid therapeutic levels are achieved, but side effects increase due to high peak concentrations
Solution Approach 1:
The administration regimen is dynamically adjusted based on the patient's renal function and response to treatment. Instead of fixed bolus dosing, the infusion rate or dosing interval is optimized to achieve the minimum effective concentration while avoiding peak levels that cause side effects. This dynamic approach allows rapid attainment of therapeutic levels without the harmful peaks associated with traditional bolus administration
3Reliability
If compounds are administered to inhibit calcium crystal formation, then cardiovascular calcification is prevented, but irreversible binding occurs reducing reliability
Solution Approach 1:
The compound is administered at controlled concentrations that achieve sufficient binding to calcium-containing crystals to prevent cardiovascular calcification, but do not exceed the threshold for irreversible binding. By using prolonged low-dose administration rather than high-dose bolus, the treatment achieves the necessary therapeutic effect while maintaining reversible binding characteristics, thus preventing calcification without the harmful irreversible attachment
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
Prevents and treats kidney failure-related diseases by maintaining therapeutic levels of compounds with C—O—P bonds, reducing side effects, and inhibiting calcium crystal formation, thereby improving patient outcomes.
Implementation Method 1
compounds with C—O—P bonds... preventing irreversible binding to calcium-containing crystals
Data Source
AI summary
Use of a derivative containing C—O—P bonds in a controlled release form to treat patients with kidney failure. Moreover, it comprises the use of said derivatives together with other active substances, which particularly may be selected from a list comprising a calcimimetic, vitamin, phosphate binder, thiosulfate, bisphosphonate, pyrophosphate, citrate, diuretic, antihypertensive and anticholesteraemic agent.